Please wait a minute...
文章检索
预防医学  2017, Vol. 29 Issue (4): 360-362    DOI: 10.19485/j.cnki.issn1007-0931.2017.04.009
  论著 本期目录 | 过刊浏览 | 高级检索 |
211例宫颈腺癌治疗患者生存预后影响因素分析
徐小仙,张筱婧,周建松,楼寒梅
浙江省肿瘤医院妇科,浙江杭州 310022
Prognostic factors affecting survival of 211 cervical adenocarcinoma patients
XU Xiao-xian, ZHANG Xiao-jing,ZHOU Jian-song, LOU Han-mei
Department of Gynecologic Radiation Oncology, Zhejiang Cancer Hospital,Hangzhou, Zhejiang,310022, China
全文: PDF(527 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 了解宫颈腺癌治疗患者生存预后的影响因素,为预防和治疗宫颈腺癌提供依据。方法 选取2008—2013年6月在浙江省肿瘤医院接受治疗的211例宫颈腺癌患者,根据病例资料和随访情况,估计生存率并分析其影响因素。结果 211例宫颈腺癌治疗患者随访10~81个月,中位数为49个月。43例患者因宫颈腺癌死亡,占20.38%。宫颈腺癌1年生存率为96.2%,3年生存率为88.6%,5年生存率为74.7%。多因素Cox分析显示,年龄(RR=4.940,95%CI:1.925~12.678)、盆腔淋巴结转移(RR=2.391,95%CI:1.311~4.360)和腹主动脉旁淋巴结转移(RR=6.344,95%CI:1.007~39.990)、FIGO分期(与I期相比,Ⅲ期:RR=5.315,95%CI:2.760~12.203;Ⅳ期:RR=9.932,95%CI:2.905~18.846)是宫颈腺癌患者生存的独立危险因素。结论 宫颈腺癌患者的年龄、FIGO分期、盆腔淋巴结转移及腹主动脉旁淋巴结转移是影响宫颈腺癌患者生存的危险因素。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
徐小仙
张筱婧
周建松
楼寒梅
关键词 宫颈癌腺癌生存率预后因素    
AbstractObjective This study was conducted to determine the prognostic factors of cervical adenocarcinoma.Methods Between July 2008 and June 2013, 211 consecutive patients were treated because of International Federation of Gynecology and Obstetrics(FIGO) stage IA-IVB cervical adenocarcinoma. Overall survival was analyzed by the Kaplan-Meier method.Results One-year OS rate was 96.2%,and 3-year OS rate was 88.6%,and 5-year OS rate was 74.7%.Patients’age,FIGO stage,postoperative clinicopathological factors such as depth of stromal invasion,number of pelvic lymph node metastasis and para-aortic lymph node metastasis,were analyzed to discriminate their prognostic role. In the univariate analysis, age,FIGO stge,deep stromal invasion, lymph-vascular space invasion, number of pelvic lymph node metastasis,para-aortic lymph node metastasis were associated with poorer survival(P< 0.05). In the cox analysis, age (RR=4.940,95%CI:1.925-12.678),pelvic lymph node metastasis(RR=2.391,95%CI:1.311-4.360),para-aortic lymph node metastasis (RR=6.344,95%CI:1.007-39.990)and FIGO stage(Ⅲ vs I,RR=5.315,95%CI:2.760-12.203;Ⅳ vs I,RR=9.932,95%CI:2.905-18.846)were independent prognostic factors of invasive cervical adenocarcinoma. Conclusion Early detection and early treatment is very important for cervical adenocarcinoma patients.Give the patient suitable and maybe more aggressive adjuvant therapy according to surgical pathology is helpful for imporving adenocarcinoma treatment.
Key wordsCervicalcancer;Adenocarcinoma;Survival rate;Prognostic factor
收稿日期: 2016-09-28      出版日期: 2017-11-21
ZTFLH:  R737.33  
通信作者: 浙江省医药卫生科技计划(2015KYA037);浙江省自然科学基金(LY13H160026)   
作者简介: 徐小仙,硕士,主治医师,主要从事妇科肿瘤的研究和治疗工作
引用本文:   
徐小仙,张筱婧,周建松,楼寒梅. 211例宫颈腺癌治疗患者生存预后影响因素分析[J]. 预防医学, 2017, 29(4): 360-362.
XU Xiao-xian, ZHANG Xiao-jing,ZHOU Jian-song, LOU Han-mei. Prognostic factors affecting survival of 211 cervical adenocarcinoma patients. Preventive Medicine, 2017, 29(4): 360-362.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn1007-0931.2017.04.009      或      http://www.zjyfyxzz.com/CN/Y2017/V29/I4/360
[1]JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90. [2]ENDO D, TODO Y, OKAMOTO K, et al. Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort[J]. J Gynecol Oncol, 2015, 26 (1):12-18.
[3]BAEK M H, PARK J Y, KIM D, et al.Comparison of adenocarcinoma and adenosquamous carcinoma in patients with early-stage cervical cancer after radical surgery[J]. J Gynecol Oncol,2014,135(3):462-467.
[4]IRIE T, KIGAWA J, MINAGAWA Y, et al. Prognosis and clinicopathological characteristics of Ib-IIbadenocarcinoma of the uterine cervix in patients who have had radical hysterectomy[J]. Eur J Surg Oncol, 2000,26(5):464-467.
[5]LEE J Y, KIM Y T, KIM S, et al. Prognosis of cervical cancer in the era of concurrent chemoradiation from National Database in Korea: a comparison between squamous cell carcinoma and adenocarcinoma[J]. PLoS One, 2015, 10(12): e0144887.
[6]VINH-HUNG V, BOURGAIN C, VLASTOS G, et al. Prognostic value of histopathology and trends in cervical cancer: a SEER population study[J].BMC Cancer, 2007(7):164.
[7]FUJIWARA H, YOKOTA H, MONK B, et al.Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma[J]. Int J Gynecol Cancer, 2014,24(9 Suppl 3):S96-101.
[8]STEHMAN F B, ALI S, KEYS H M, et al. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma : follow-up of a Gynecologic Oncology Group trial[J]. Am J Obstet Gynecol, 2007,197(5): 503. e1-e6.
[9]FIGO Committee on Gynecologic Oncology.FIGO staging for carcinoma of the vulva, cervix, and corpus uteri[J].Int J Gynaecol Obstet, 2014,125(2):97-98.
[10] 钟钰平,沈建生,向吉萍,等. 农村妇女宫颈癌筛查结果[J].浙江预防医学,2012,24(11):53-54
[11]钱小萍,范水娟,姚慧. 15 881名农村妇女宫颈癌筛查结果[J].浙江预防医学,2014,26(6):627-628.
[12] LAI C H, CHANG C J, HUANG H J, et al. Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery[J]. J Clin Oncol, 2007,25(24): 3628-3634.
[13]DOUINE M, ROUE T, FIOR A, et al. Survival of patients with invasive cervical cancer in French Guiana, 2003-2008[J].Int J Gynaecol Obstet, 2014,125(2):166-167.
[14]BAALBERGEN A, EWING-GRAHAM P C, HOP W C, et al. Prognostic factors in adenocarcinoma of the uterine cervix[J]. J Gynecol Oncol,2004,92(1):262-267.
[15]喻芳明,陈亚侠,聂桂兰,等.宫颈癌患者盆腔淋巴结转移高危因素分析[J].浙江预防医学,2015,27(10):995-998.
[1] 邢洁, 朱笕青, 于爱军, 郑爱文. 浙江省高危HPV基因型分布热力图分析[J]. 预防医学, 2019, 31(8): 851-853.
[2] 金孔军, 周悦, 综述;葛学娣, 审校. 大学生人群HPV疫苗认知及影响因素研究进展[J]. 预防医学, 2019, 31(5): 470-473.
[3] 何友梅, 吴小芬, 陶国芝. 宫颈上皮内瘤变患病危险因素分析[J]. 预防医学, 2017, 29(5): 524-526.
[4] 喻芳明,叶滕,苏杨娜,毛广运,施小柯,张本龙. p53基因第4外显子第72密码子多态性与中国女性宫颈癌相关性的Meta分析[J]. 预防医学, 2016, 28(8): 770-775.
[5] 李红儿,童玮如,陆玉莲,沈晓红,徐畅. 宫颈上皮内瘤变Ⅱ级的危险因素及干预效果分析[J]. 预防医学, 2016, 28(6): 634-637.
[6] 应亚君, 张建民, 林艳. 温岭市已婚女性宫颈癌筛查结果分析[J]. 预防医学, 2018, 30(3): 306-307.
[7] 张亚萍,林启. 舟山市宫颈癌发病及死亡分析[J]. 预防医学, 2017, 29(2): 200-201.
[8] 黄慧伟, 邓茜, 辛青, 吴磊, 余超, 周伟. TCT、高危型HPV、hTERC和Se联合检测筛查宫颈癌[J]. 预防医学, 2019, 31(10): 1057-1060.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed